Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bioventus Q2 Adj. EPS $0.21, Inline, Sales $147.660M Beat $146.284M Estimate

Author: Benzinga Newsdesk | August 06, 2025 06:03am
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $147.660 million which beat the analyst consensus estimate of $146.284 million by 0.94 percent. This is a 2.35 percent decrease over sales of $151.217 million the same period last year.

Posted In: BVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist